Pacira Pharma (PCRX) Posts Wider than Expected Loss; Reiterates FY11 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) reported Q1 loss of $0.98, $0.45 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $4.16 million.
Reiterates FY11 revs outlook.
Reiterates FY11 revs outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) Tops Q3 EPS by 84c, Misses on Revenue, Raises FY Guidance
- Infosys Limited (INFY) Reports In-Line Q3 EPS
- PharmaCorp to Present as Planet Microcap Toronto 2026 Conference
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
